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Abstract
Background—The daunting task for drug molecules to reach pathological lesions has fueled
rapid advances in Nanomedicine. The progressive evolution of nanovectors has led to the
development of multi-stage delivery systems aimed at overcoming the numerous obstacles
encountered by nanovectors on their journey to the target site.
Scope of Review—This review summarizes major findings with respect to silicon-based drug
delivery vectors for cancer therapeutics and imaging. Based on rational design, well established
silicon technologies have been adapted for the fabrication of nanovectors with specific shapes,
sizes, and porosities. These vectors are part of a multi-stage delivery system that contains multiple
nano-components, each designed to achieve a specific task with the common goal of site-directed
delivery of therapeutics.
Major Conclusions—Quasi-hemispherical and discoidal silicon microparticles are superior to
spherical particles with respect to margination in the blood, with particles of different shapes and
sizes having unique distributions in vivo. Cellular adhesion and internalization of silicon
microparticles is influenced by microparticle shape and surface charge, with the latter dictating
binding of serum opsonins. Based on in vitro cell studies, the internalization of porous silicon
microparticles by endothelial cells and macrophages is compatible with cellular morphology,
intracellular trafficking, mitosis, cell cycle progression, cytokine release, and cell viability. In vivo
studies support superior therapeutic efficacy of liposomal encapsulated siRNA when delivered in
multi-stage systems compared to free nanoparticles.
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1. Introduction
Nanotechnology pertains to synthetic, engineerable objects which are nanoscale in
dimensions or have critical functioning nanoscale components, leading to novel, unique
properties [1–2]. These emergent characteristics arise from the material’s large surface area
and nanoscopic size [3]. Nanotechnology now occupies a niche as a burgeoning and
revolutionary field within medicine known as nanomedicine, particularly within the field of
oncology [1]. One of the potential benefits of nanomedicine is the creation of nanoparticle
based vectors that deliver therapeutic cargo in sufficient quantity to a target lesion to enable
a selective effect. This is a daunting task for all drug molecules, owing to the highly
organized array of ‘biological barriers’ that the molecules encounter [3–6]. The human body
presents a robust defense system that is extremely effective in preventing injected chemicals,
biomolecules, nanoparticles and any other foreign agents from reaching their intended
destinations. Biobarriers are sequential in nature, and therefore, the probability of reaching
the therapeutic objective is the product of individual probabilities of overcoming each
barrier [7–8]. Sequentially, with respect to intravascular injections, these comprise:
enzymatic degradation; sequestration by phagocytes of the reticulo-endothelial system
(RES) [9–10]; vascular endothelia [11]; adverse oncotic and interstitial pressures in the
tumor [12–13]; cellular membranes, or subcellular organelles such as the nucleus and
endosomes [14–15]; and molecular efflux pumps [16]. Without an effective strategy to
negotiate these barriers, new or current therapeutic agents based on enhanced biomolecular
selectivity may yield sub-optimal utility, simply because they reach the intended targets in
very small fractions, with only 1 in 10,000 to 1 in 100,000 molecules reaching their intended
site of action [7]. Due to this narrow therapeutic window, marginal tolerability and
considerable mortality ensue [17]. Transport through different compartments and across
biological barriers can be enhanced by optimization of particle size, shape, density and
surface chemistry. These parameters dominate transport in the bloodstream, margination,
cell adhesion, selective cellular uptake, and sub-cellular trafficking.
An early obstacle for intravascularly administered therapeutics is the endothelial wall which
forms the boundary between the circulatory system and tissue specific microenvironments.
Specific adherence of delivery vectors to diseased vasculature provides a key to conquering
this early barrier, as does the hijacking of cells bound for the inflammatory
microenvironment of the lesion. In order to efficiently overcome various biobarriers
multiple levels of targeting, spatial release of secondary carriers or therapeutics,
simultaneous delivery of independent systems or systems with a synergistic impact should
be considered. The purpose of this review is to present the multi-stage concept of drug
delivery and to summarize the experimental techniques and research findings that have
transpired from this area of research.
2. Nanovector taxonomy
A variety of nanocarrier-based drug delivery systems with different compositions, geometry,
and surface modifications are under various stages of investigation [1,18], producing an
enormous collection of nanoparticles with a large array of possible combinations. Figure 1
illustrates three main categories of nanovectors that have been described based on their
functions and capabilities [1,19–20]. First generation nanovectors are the most elementary,
and home to diseased sites by passive mechanisms such as the enhanced permeation and
retention (EPR) effect, or more specifically, extravasate through gaps in tumor neo-
vasculature. Avoidance of uptake by the RES is through functionalization with neutral
polymers, such as poly(ethylene glycol) (PEG) [21–23]. Interactions between the aqueous
environment and the hydrophilic polymers permits extension and mobility of the polymeric
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chains [24]. Derivatized nanoparticles adsorb plasma components more slowly [25] based
on steric repulsion forces [26], negating opsonin driven uptake of nanoparticles by
phagocytic cells, and enhancing blood circulation time. Advantages of nanoparticle-based
carriers include improved delivery of water insoluble drugs, prolonged circulation half life,
and reduced immunogenicity [27–28].
The second category of nanovectors is comprised of delivery systems with an additional
functionality [29–33], including: (a) targeting of the disease site through ligands that
specifically bind to receptors uniquely- or over-expressed in the tumor microenvironment;
(b) advanced functionalities, including co-delivery of multiple therapeutics or imaging
agents, or triggered or controlled release of therapeutic agents. More sophisticated than their
predecessors, the second generation of nanovectors represents a progressive evolution of
first-generation nanovectors.
The third generation of nanovectors represents a paradigm shift in the strategy to overcome
numerous obstacles encountered by nanovectors on their journey to the target site. Since no
single agent can conquer the plethora of barriers that exist, these nanovectors are comprised
of diverse families of nanoparticles nested into a single vector to achieve collaborative
interactions. These carriers, or Logic Embedded Vectors (LEVs) [8], are therapeutic, multi-
component constructs specifically engineered to avoid biological barriers, in which the
functions of biorecognition, cytotoxicity and biobarrier avoidance are decoupled, yet act in
efficacious, operational harmony. As an example of this therapeutic strategy, one can
envision a vector which effectively navigates through the vasculature based on its geometry,
attaches to the diseased vascular site through specific surface recognition and releases
different nanoparticle payloads that simultaneously and synergistically extravasate, reach
tumor cells and deliver their active agents at optimal concentrations to selectively eliminate
malignancy with minimal side effects. This concept describes the multi-stage delivery
system that will be extensively reviewed in this paper. By definition, third generation
nanovectors have the ability to perform a time sequence of functions through the use of
multiple nano-based components that synergistically provide distinct functionalities.
In addition to the multi-stage delivery system, an example of third generation nanoparticles
is biologically active molecular networks called “nanoshuttles”, which are self-assemblies of
gold nanoparticles within a bacteriophage matrix. Nanoshuttles combine the hyperthermic
response of a near-infrared or radiofrequency external energy of the gold with the biological
targeting capabilities of the 4C-RGD sequence presented by the phage [32,34]. These
nanoshuttles collectively accommodate enhanced fluorescence, dark-field microscopy, and
surface-enhanced Raman scattering detection.
Another example of a third generation nanovectors is the “nanocell”, based on a disease-
inspired approach to therapy. [35]. Utilizing the combinatorial chemotherapy approach,
researchers have developed a nested nanoparticle construct that comprises a lipid-based
nanoparticle enveloping a polymeric nanoparticle core called a “nanocell”. A conventional
chemotherapeutic drug, doxorubicin, is conjugated to a polymer core and an anti-angiogenic
agent, combretastatin, is then trapped within the lipid envelope. When nanocells accumulate
within the tumor through the EPR effect, the sequential time release of the anti-angiogenic
agent, and then the cytotoxic drug, causes an initial disruption of tumor vascular growth and
effectively traps the drug conjugated nanoparticle core within the tumor to allow eventual
delivery of the cancer cell killing agent.
Silica and silicon-based delivery systems represent the final example of third generation
nanovectors. Mesoporous silica nanoparticles have been developed to co-deliver
doxorubicin and Bcl-2 siRNA by encapsulation of doxorubicin inside the pores and
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complexation of siRNA in a dendrimer shell [36]. The goal of this nanodevice is to
simultaneously deliver an anticancer drug as an apoptosis inducer and siRNA molecules as
suppressors of membrane pumps that mediate multidrug resistance. This multi-component
nanodevice was able to significantly enhance the cytotoxicity of doxorubicin by decreasing
the IC50 64-fold.
Mesoporous silicon devices include our multi-stage system [37]. Based on well established
semiconductor microfabrication lithography techniques, which allow for exquisite control of
size, shape, and porosity, in concert with active biological targeting moieties, these vectors
are intended to deliver large payloads of nanoparticles and higher order therapeutic and
imaging agents to the tumor site. The “stage one” mesoporous silicon microparticles are
designed based on mathematical modeling to exhibit superior margination and adhesion
during their navigation through the systemic circulation. Stage one particles shoulder the
burden of efficiently transporting, shielding, and controlling the rate of release of the
nanoparticle payload. The encapsulated nanoparticles, called “stage two” nanoparticles, can
be any nanovector construct within the approximate diameter range of 5–100 nm. The multi-
stage drug delivery system is an example of LEVs which strategically combine numerous
nano-components aimed at delivering single or multiple component nanovectors to the
tumor site. The stage one particle is rationally designed to have a hemi-spherical or discoidal
shape to enhance particle margination within the blood, as well as interactions between
particles and endothelia, with a goal of maximizing the probability of active tumor targeting
and adhesion [107]. In addition to improved hemodynamic properties and active biological
targeting utilizing nano-components such as aptamers and phages, as will be discussed
below, the stage one particles may also present specific surface modifications to avoid RES
uptake. Following recognition of tumor vasculature and firm vascular adhesion, a series of
nanoparticle payloads may be released in a sequential order dictated by diffusion from
expanding or newly opened nanopores. Factors governing nanoparticle release include stage
one particle degradation rates, polymeric coating, and stage two design strategies (e.g.,
environmentally sensitive cross-linking techniques with pH, temperature, and/or enzymatic
triggers). We have observed that the degradation rate of the porous silicon particles is
proportional to its porosity, and can be tuned from hours to days without surface
functionalization. The versatility of this multi-stage delivery platform allows for a
theranostic approach to therapy, including the delivery of chemotherapeutics, remotely
activated hyperthermic nanoparticles, image contrast agents, and sequential, sustained
release of successive stages of nanoparticle and active agents.
3. Rational design of stage one particles
The rational design of nanovectors aims at finding the dominating governing parameters in a
series of events which are encountered as the particle travels from the site of administration
to the intended site of action. Multi-stage vectors are transported in the blood stream,
interact with the vascular endothelium, and eventually interact with endothelia in the tumor
neovasculature. These three fundamental events in the intravascular “journey” provide the
basis for rational design, including: (1) the margination dynamics, (2) firm adhesion, and (3)
control of internalization. The term ‘margination’ is used in physiology to describe the
lateral drift of white blood cells and platelets from the center of the blood vessels towards
the endothelial walls. The rational design of particles aims at generating a marginating
particle that can spontaneously move preferentially in close proximity to the blood vessel
endothelium [38–39]. Unlike spherical particles, non-spherical particles exhibit more
complex motions with tumbling and rolling which can be exploited to control their
margination dynamics without any need for lateral external forces. The longitudinal (drag)
and lateral (lift) forces, as well as the torque exerted by flowing blood, depend on the size,
shape, and orientation of the particle, as well as the stream direction and vascular changes
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that the particle encounters as it transverses through the bloodstream. For example, if one
considers an elongated particle with an aspect ratio of 2, the particle motion becomes very
complex with periodic oscillations towards and away from the wall [38]. Overall, however,
the particle tends to approach the wall and periodically interact with its surface. More
recently, in-vitro experiments conducted using spherical, discoidal and quasi-hemispherical
particles with the same weight injected into a parallel plate flow chamber under controlled
hydrodynamic conditions have shown that discoidal particles tend to marginate more than
quasi-hemispherical particle, and both of these marginate more than spherical particles
(Figure 2) [40–41]. It was also shown that the probability of adhesion is decreased as a result
of increasing shear stress at the vessel wall and particle size. Cellular adhesion increases as
the surface density of ligand molecules on the particle surface and receptor molecules on the
cell membrane increase. For all particle shapes, a characteristic size can be identified for
which the probability of adhesion has a maximum. [42]. For example, hydrodynamic forces
decrease as particle size decreases, but the area of interaction at the particle/cell interface is
also reduced, leading to fewer ligand-receptor interactions and reduced potential to
withstand even small dislodging forces. For larger particles, the number of ligand-receptor
bonds increases, but so do the hydrodynamic forces on the particles. With respect to particle
adhesion, rational design seeks to optimize binding strength by modulation of particle shape
and a balance between ligand surface density and binding affinity.
There are different mechanisms in vivo which govern the behavior of particles. Recent
studies have demonstrated that particles of different shape have unique biological
distributions (Figure 3) [43]. Six hours after systemic injection in mice, hemispherical
particles accumulated preferentially in the liver, with minimal distribution to the heart and
lungs, while discoidal particles showed relatively less retention in the liver, and high
accumulation in the heart and lungs, as well as the spleen. Approximately 2% of the
hemispherical particles accumulated in the tumor, which is significantly [43] greater than 1
in 10,000 (0.01%) biomolecularly targeted therapeutic agents. In vivo studies recently
published support superior therapeutic efficacy of multi-stage delivered liposomal siRNA
over first generation siRNA liposomes [44]. In this work, a single injection of siRNA in a
multi-stage construct resulted in gene silencing equivalent to six injections of liposomal
siRNA delivered over three weeks. These findings suggest that higher level targeting is
achieved by second-stage vectors and/or therapeutic agents, perhaps by means of sustained,
long term release of secondary agents from the first stage porous silicon vector.
There have been significant improvements in tumor accumulation (2–25 times higher) and
therapy with PEGylated liposomal agents currently in clinical use as compared to non
sterically- stabilized liposomes and to the free drug [45]. However, numerous reports state
that the main fraction of the drug still accumulates in the filtering organs, with therapeutic
loss of the drug [46–47]. With the multi-stage system, a comparable fraction of the multi-
stage vector reaches the tumor; moreover, the fraction captured in the filtering organs is not
therapeutically “lost”. As demonstrated in the multistage siRNA therapy study, porous
silicon carriers trapped in the filtering organs slowly released second stage particles which
were then able to migrate to target tissue, efficiently suppressing tumor growth for more
than 21 days.
4. Fabrication of geometrically diverse stage one silicon particles
First stage nanoporous silicon particles are fabricated according to the edict of rational
design for optimal performance, including: 1) Margination and adhesion; 2) Loading with
Stage two nanoparticles; and 3) Control of degradation and release of secondary
nanoparticles. Particles with determined size, shape and porous structure can be fabricated
through a combination of photolithographic techniques and electrochemical etch [48–49]
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(Figure 4). A thin masking layer of SiN is deposited on the silicon substrate, followed by
spinning for photoresist development. The photoresist is patterned with the desired
photomask and the pattern is transferred into the substrate by dry reactive ion etch. The
substrate is then selectively porosified according to the lithographic pattern by anodic
electrochemical etch in a solution of hydrofluoric acid and ethanol to obtain porous silicon
particles that can be released from the substrate. The resulting particle maintains a central
nucleation site in the size and shape of the photolithographic pattern, surrounded by an
external corona whose thickness is determined by the electrochemical etch. This
straightforward process can be controlled at each step to fine tune the physical properties of
the resulting particle. Choosing the size and shape of the photolithographic pattern
determines the size and shape of the particle nucleation site, influencing the overall size and
shape. Our group has successfully fabricated particles with a circular nucleation site of size
ranging from 400 nm to over 5 µm. The timing and gas composition of the dry reactive ion
etch controls the depth and shape of the trenches formed in the silicon substrate, determining
the aspect ratio and the profile of the resulting porous silicon particle. Shorter etch time
creates shallow, high aspect ratio (up to 6) discoidal particles; while longer etch times yield
thicker, quasi-hemispherical particles with aspect ratios ranging from 1 to 2. The substrate
resistivity and doping type, timing, current density and solution composition during the
electrochemical etch determine the thickness of the porous layer, the pore size and particle
morphology[48–51]. Increasing resistivity, larger currents, and higher concentrations of
ethanol with respect to hydrofluoric acid all contribute to the increase in pore size. Pore size
larger than 20 nm is associated with straight, unbranched pores, while pores in the 10–20 nm
size range show a branched tree-like structure. Pores smaller than 10 nm yield a randomly
oriented network structure.
5. Loading porous silicon particles with second stage nanoparticles
Pore size and morphology affect particle loading, payload retention, and release kinetics
[37]. We have shown that particles with 5 nm diameter pores can be loaded efficiently with
2×30 nm Single Wall Carbon Nanotubes (SWNTs), while 5 nm CdSe Quantum Dots
(Qdots) are associated solely with the particle surface. Conversely, particles with 20 nm
pores are capable of loading both SWNTs and the Qdots within the porous structure [37].
We have demonstrated sustained release of both Qdots and SWNTs from 20 nm pores over
the course of 24 hr.
Success at loading secondary nanoparticles into the porous silicon matrix is best achieved
using dry silicon particles. Loading then occurs by adding a concentrated solution of
nanoparticles that is pulled into the pores by capillary action, i.e. the incipient wetness
method [52–54]. Optimization of loading takes into account pore size, dimensions of the
payload, surface charge or functionalization, and solvent optimization.
Alternately, loading has been achieved by covalent attachment of nanoparticles to the silicon
surface. Successful loading has been demonstrated with 3-aminopropyltriethoxysilane
(APTES) modified silicon microparticles and carboxylated iron oxide and gold
nanoparticles using Sulfo-N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide chemistry. Scanning electron micrographs, displayed in Figure 5, show quasi-
hemispherical silicon microparticles covalently loaded with gold nanoparticles (6 nm core)
before (top left) and following cellular uptake (top right). The accompanying 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) proliferation assay shows
similar rates of cell growth in the presence of control or gold loaded porous silicon particles
at ratios of 5 and 10 silicon particles per cell.
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6. Targeting
Advances in tumor targeting have turned Paul Ehrlich’s once-outlandish concept of a
“magic bullet,” where malignancies in the body can be treated by chemical substances
equipped with high affinity for that malignancy,[55] into a very attainable goal. Thanks to
significant strides in research concerning phage display libraries, it is now feasible to
increase the affinity of nanoparticles for specific targets in these diseased states. This in turn
results in increased amounts of nanoparticles concentrated at the site of action, permitting
drug or imaging agents to exert their effects locally. In the case of targeted
chemotherapeutics, enhanced efficacies result, and toxicity to healthy tissues and organs is
substantially reduced. With regard to imaging agents, the increased amassing of
nanoparticles at the site of action allows for enhanced contrast and proper delineation of
tumor boundaries. In light of the overwhelming benefits of active targeting, the attachment
of ligands to the surface of nanoparticles is presently an area of intense research. The ligands
currently under active exploration, and those with the most clinical potential, include the
following: peptides, thioaptamers, small organic compounds, carbohydrates, and antibodies.
During the process of angiogenesis and vascular remodeling in tumors, endothelial cells
demonstrate an over expression of cell surface markers critical for cell proliferation and
invasion, leading to lesion specific “zipcodes”, or vascular addresses. These markers include
several receptors and integrins, the principle ones being vascular endothelial growth receptor
(VEGF) and the αvβ3 integrin [56]. Given their over expression on the surface of tumor
vasculature endothelia, as well as the fact that blood is in constant contact with endothelial
cells, these receptors and integrins are very attractive markers for tumor targeting. Phage
display technology is used to map vascular zipcodes, that is, protein interacting sites. The
benefits of phage technology include genetic manipulation, high throughput screening, and
production in high titers (via propagation in host bacteria) [57]. Libraries of peptides are
displayed on the surface of bacteriophage, then tested against target cells or in vivo, leading
to isolation of target specific peptides by multiple rounds of “biopanning”. Bound peptides
are recovered and the sequence is screened against databanks to identify sequence homology
with existing motifs. For example, the RGD-4C peptide, isolated by in vivo phage display, is
currently being used as a tumor homing peptide for first stage vectors via targeting of
integrins.
Gao and coworkers were able to conjugate a cyclic Arg-Gly-Asp-D-Phe-Lys (cRGD)
peptide to the surface of polymer micelles that encapsulated superparamagnetic iron oxide
nanoparticles [58]. Once administered intravenously, the polymer micelles were able to
actively target A549 lung tumors implanted subcutaneously in mice, leading to enhanced
tumor imaging under MRI as compared to non-targeted micelles.
Another option for targeting includes aptamers, oligonucleotide molecules that are selected
based on their affinity for the native tertiary structure of target molecules expressed on the
cell surface [59]. Modification of one or both of the phosphoryl non-bridging oxygen atoms
of the aptamer with sulfur creates “thioaptamers” with increased resistance to nucleases,
tighter binding, and reduced negative charge leading to enhanced cellular uptake of aptamer
decorated nanoparticles. The aptamers can be thio-modified enzymatically and the resulting
oligonucleotides have been shown to be rapidly cleared by the renal system. Hybrid
thioaptamers, with a mix of thiophosphate and unmodified phosphate are the best option for
specificity, nuclease resistance, and high affinity.
Ramakrishnan and coworkers showed that a VEGF-toxin conjugate (VEGF165-DT385),
administered intraperitoneally, was able to target a subcutaneous human ovarian cancer cell
xenograft (MA148) in mice, leading to tumor growth delay.[60] Cheresh and coworkers
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synthesized a cationic polymer lipid-based nanoparticle fashioned with a small organic αvβ3
ligand [61]. After 24 hours, these nanoparticles, which also contained a gene encoding
firefly luciferase, were observed in human melanoma cells over expressing αvβ3. It is
important to note that nanoparticles were rarely observed in healthy organs and tissues.
Folic acid represents a small organic molecule used for tumor targeting, given that the
receptor for folic acid is a protein overexpressed in many different cancer cells [62].
Doxorubicin polymer micelles fashioned with folic acid, developed by Park et al., showed
increased uptake in KB cells in vitro, with in vivo work showing a significant decrease in
tumor growth rate when compared to non-targeted micelles [63]. Carbohydrate molecules
have been used to target hepatocellular carcinoma, given the overexpression of the
asialoglycoprotein receptor (ASGPR), a membrane lectin receptor, on these cells [64]. The
most studied carbohydrate molecules for targeting include galactose and lactose. Cho et al.
demonstrated a 30% increase in paclitaxel-loaded polymer micelles in cells overexpressing
ASGPR as compared to cells that did not express the receptor [65].
Monoclonal antibodies, which possess high binding affinities, are also actively being
explored as tumor-specific targeting modalities. Trastuzumab, a humanized monoclonal
antibody specific for the HER2/neu receptor (erbB2), is an FDA approved drug used for the
treatment of HER2-positive breast cancer [66]. Trastuzumab causes cell cycle arrest leading
to decreased cancer cell proliferation and reduced angiogenesis. Antibodies specific for
HER2 have been used as targeting ligands for selective delivery of silica gold nanoshells to
tumor tissue [67]. Other antibody-based targeting agents include monoclonal antibodies
specific alphavbeta3 [68], which when covalently coupled to human serum albumin
nanoparticles, resulted in enhanced binding to melanoma cells. Monoclonal antibodies
against alphavbeta3 integrin were also shown to inhibit both cancer growth and angiogenesis
[68].
7. Therapeutic applications of multi-stage delivery systems
Nanotechnology is projected to fill the gap between significant scientific advances in the
areas of cancer imaging and diagnosis, discovery and development of a plethora of
anticancer drugs, and their translation into improvements in cancer management. With
optimal anticancer treatment regimens still lacking, novel therapeutic approaches are being
explored to supplement or replace traditional gold standards, including surgical resection
[69] and radiation therapy [70]. While the curative potential of anticancer drugs is
indisputable, limitations that hinder clinical translation and success include nonspecific drug
delivery. In this section, we describe various “stage two” nanoparticles that have been
successfully incorporated in the multi-stage system for various therapeutic applications.
7.1 Liposomes
Liposomes represent a nanotherapeutic modality that shows immense clinical potential for
drug delivery. These vesicular nanostructures, formed from phospholipid and cholesterol
molecules, possess several advantages for drug delivery. First, their inner hydrophilic
compartment can encapsulate water-soluble drugs, as well as therapeutic proteins, DNAs,
and siRNAs. Second, with a diameter in the range of 100 nm, the drug payload can be
substantial. Lastly, their functionalizaton with PEG can grant them with stealth-like
properties, avoiding uptake by the RES. The chief disadvantage to liposomal drug delivery
is the inability to encapsulate poorly soluble drugs within the aqueous core, limiting
encapsulation of drugs to the hydrophobic bilayer membrane. A PEGylated liposomal
formulation, known as Doxil®, is currently in clinical trials for the treatment of Kaposi’s
sarcoma [71]. These stealth liposomes have long blood circulation times over non-
PEGylated liposomes, and readily accumulate in tumors due to passive targeting [72–73].
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Another drug that was successfully encapsulated in liposomes is annamycin, a non-cross-
resistant anthracycline [74]. The pre-liposomal annamycin lyophilized powder contains
phospholipids (dimyristoylphosphatidyl choline and dimyristoylphosphatidyl glycerol at a
7:3 molar ratio), annamycin (lipid:drug at a ratio 50:1 w/w), and Tween 20. The surfactant
in the formulation allows for better solubilization of the drug, shortening the reconstitution
step, as well as a means to form nano-size carriers without destroying the liposomal
structure [75]. Similar to doxorubicin, the drug possesses native fluorescence in the red
region. In Figure 6, we show flow cytometry data supporting loading of annamycin
liposomes into porous silicon microparticles. Loading resulted in a shift in the mean
fluorescent intensity from 3 to 1285 AU. Other liposomal active agents that were
successfully loaded into the multi-stage drug delivery system include paclitaxel, doxorubicin
and siRNA. In vitro and in vivo efficacy studies with these systems in various cancer models
are underway.
7.2 Polymer micelles
Ringsdorf and coworkers worked in the early 1980s on the development of polymer micelles
as drug delivery vehicles [76]. These spherical, supramolecular constructs, with a size
ranging from 10–100 nm, are formed from the self-assembly of biocompatible amphiphilic
block copolymers in aqueous environments [77–79]. The hydrophilic outer portion, typically
composed of PEG, forms a hydrating layer, while the hydrophobic core, composed of
polymers such as poly(D,L-lactic acid) (PDLLA), poly(ε-caprolactone) (PCL), and
poly(propylene oxide) (PPO), houses the anticancer agent. The ability of the drug to be
encapsulated within the hydrophobic core represents their main advantage, in addition to
their innate possession of a PEG hydrophilic corona that prevents opsonization and RES
uptake [80], and their small size which leads to their preferential accumulation in tumor
tissue through the EPR effect.
Currently, several polymeric micelle platforms are being explored in clinical trials. Kataoka
and coworkers formulated doxorubicin-containing poly(ethylene glycol)–poly(L-aspartic
acid) micelles [79]. This formulation, known as NK911, displayed long blood circulation
times and nearly tripled the half-life of doxorubicin [81]. Genexol-PM is another micelle
formulation in clinical trials, and consists of PEG-PLA micelles that encapsulate paclitaxel.
Findings showed that Genexol-PM was much more tolerable than the clinically used
formulation of paclitaxel containing Cremephor® EL, a formulation that results in
hypersensitivity reactions [82]. As a result, the dose of paclitaxel administered to patients
could be increased, which in turn resulted in enhanced anti-tumor efficacy in patients [83–
84].
To further enhance selective delivery of chemotherapeutics to the lesion, doxorubicin and
paclitaxel polymeric micelles have been loaded into the nanoporous matrix of the silicon
microparticles (data not shown). For doxorubicin the best loading was obtained with 1,2-
distearoyl-phosphatidyl ethanolamine-methyl-poly(ethyleneglycol) anionic micelles loaded
into oxidized porous silicon microparticles. In vivo efficacy studies for cancer therapy are
currently underway.
8. Biocompatibility
8.1 Directed opsonization of silicon microparticles
The composition and physical characteristics of particles influences both their physical
properties [85–86] (e.g. electromagnetic), and their biological attributes [87–88]. Size,
shape, chemical composition, and surface charge all strongly influence the impact nano- and
micron-size particles have on cellular systems, leading to differences in biocompatibility. To
explore the biological properties of our stage one porous silicon microparticles, the impact
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of particles of different sizes and surface modifications on interactions with macrophages
and endothelial cells has been characterized.
For therapeutic and imaging applications, nanoparticles and microparticles may be
administered intravenously. During transport in the blood stream, these particles become
coated with serum components that adsorb to the particle surface. Associations between
cells and particles are regulated in part by serum proteins adsorbed to the nanoparticle
surface. These surface-bound components are referred to as either opsonins or dysopsonins,
depending on their impact, which either favor or disfavor cellular binding and uptake. One
method to reduce serum protein binding is to coat particles with a neutral polymer that
reduces cellular uptake, such as PEG. A second strategy is to alter the particle surface to
attract serum components that enhance binding to target cell populations [87].
As previously stated, the target of stage one nanoporous silicon microparticles is diseased
vasculature. As previously discussed, during many pathological states, including cancer,
inflammation alters surface moieties expressed on vascular endothelia. To simulate
inflammatory conditions in vitro, endothelial cells were treated with TNF-α for 48 hr and the
impact on cellular association with silicon microparticles was monitored by using the
increase in orthogonal light scatter by cells upon association with particles as a metric for
binding and cellular uptake. Serum components binding to oxidized silicon microparticles,
as well as negatively charged polystyrene microparticles, inhibited particle association with
endothelial cells, while factors binding to positive, APTES-modified silicon microparticles
had no impact on microparticle association with endothelial cells. Stimulation with TNF- α
further increased association of microparticles with endothelial cells. While opsonization of
oxidized silicon microparticles with pure IgG similarly inhibited association with
endothelial cells, it enhanced association with macrophages, which express receptors for
immunoglobulin (e.g. FcγRII). These findings indicate that it may be possible to manipulate
particle surface attributes to direct opsonization for selective targeting of cell populations.
8.2 Cellular engulfment of stage one silicon microparticles
Benefits of cellular uptake of drug delivery particles include cell specific killing, molecular
imaging, altered gene or protein expression, protein modification, and transcellular
transport. Cellular uptake of nanoporous silicon microparticles has been explored using real-
time confocal microscopy, scanning electron microscopy, and flow cytometry in two
subclasses of endothelial cells, Human Umbilical Vein Endothelial Cells (HUVECs) and
Human MicroVascular Endothelial Cells (HMVECs) [89]. Initial experiments compared
cellular uptake of labeled (Dylight-594; Pierce) versus label-free particles. Using flow
cytometry-derived side scatter as a metric for cellular uptake of microparticles, cellular
association with labeled particles was found to be equivalent to label-free particles.
Similarly, labeling of cells with variable amounts of dyes (i.e. CellTracker Green;
Invitrogen; 0.25–2 µM) did not impact cellular association with microparticles. Confocal
imaging of a single cell demonstrated membrane expansion around a microparticle at
approximately 5–7 min after particle contact with the cell [89].
In Figure 7, scanning electron micrographs show two sizes [1.6 (top row) and 3.2 (bottom
row) µm] of porous silicon microparticles bound to the surface of HUVEC endothelial cells
[88]. Pseudopodia, projecting from the cell surface, are seen “looping” around both 1.6 and
3.2 µm particles 15 min after introduction at 37°C. The membrane eventually spreads
outward to engulf the microparticles, as evidenced for one microparticle in Figure 7B, which
is seen oriented perpendicular to the cell membrane. Actin cup formation and engulfment of
microparticles by endothelial cells are shown in transmission electron micrographs in Figure
8 [87]. Based on particle size (> 1 µm), outward membrane extension during uptake, and
inhibition of uptake by Cytochalasin B [87], an inhibitor of actin polymerization, the
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mechanism of uptake was shown to be phagocytosis. Macropinocytosis, a second actin-
driven mechanism of cellular uptake involving membrane ruffle formation, also appears to
play a role in cellular uptake of silicon microparticles [87].
To determine the kinetics for internalization of microparticles a double fluorescent/FRET
based assay was developed [89]. Intermolecular FRET was found to occur between FITC
and PE fluorophores when FITC-labeled antibody, bound to the surface of endothelial cells,
was coupled with a secondary PE labeled antibody. Emission from the FITC fluorophore is
quenched upon binding of the secondary antibody, and cells appear positive for the PE
fluorophore only. Cells with both surface-bound (quenched, PE positive) and internalized
(protected; FITC positive) microparticles, are positive for both FITC and PE. Cells
containing only internalized microparticles are green (FITC positive) only. Using the double
antibody assay, the time for internalization of half of the microparticles was 15.7 min. Using
flow cytometry to measure cellular association with microparticles in the presence of
different ratios of particles to cells, cellular association was found to be identical for
HUVECs at passages 5 and 8, and for HMVECs [89].
8.3 Cellular compatibility of stage one porous silicon microparticles
In order to validate the biological safety of therapeutic devices, it is essential to evaluate
normal biological processes and the effect of devices on these events. The biological impact
of porous silicon vectors has been evaluated in two cell lines representing the immune
system (i.e. macrophages) and a potential physiological target or barrier to delivery (i.e.
endothelial cells). Cellular morphology, cell viability, impact on cell cycle, mitotic potential
and pro-inflammatory responses following cellular engulfment of silicon microparticles
have been demonstrated [88]. Both cell types internalize microparticles adhering to the cell
surface by phagocytosis, with subsequent intracellular transport of vesicles to the
perinuclear region of the cell [87]. Mitotic partitioning of endosomes during cellular mitosis
is an event mediated by cytoskeletal processes. We have shown that endothelial cells with
internalized silicon microparticles undergo normal cellular proliferation, and cells with as
many as 30 internalized silicon microparticles display even partitioning of microparticle-
bearing endosomes to daughter cells during mitosis (Figure 9) [88]. Figure 9 is a series of
phase contrast confocal micrographs of unstained, live cells undergoing mitosis. The cells
were imaged in five focal planes at 5 minute intervals for 19 hours and select still shots are
presented. Completion of cytokinesis, the final stage of mitosis, is dependent on polarized
delivery of endocytic recycling membranes, and the finding of polarized delivery of
microparticle-bearing vesicles to daughter cells supports a non disruptive role for
internalized microparticles. The number of microparticles per cell was also monitored as a
function of time over six days. At each cell doubling time for HMVECs (48 hr) the number
of microparticles per cell was reduced by 50%, supporting equal partitioning of
microparticle-bearing vesicles over multiple mitotic events [88].
Undisturbed endothelial proliferation and lack of cytotoxicity following internalization of
silicon microparticles was also supported by an MTT assay, which measures mitochondrial
enzyme activity (Figure 5). Control silicon microparticles and those covalently loaded with
either iron oxide (10 nm core) or gold (6 nm core) nanoparticles did not alter cellular
proliferation of endothelial cells over 72 hrs. Similar data has been obtained for
macrophages.
The impact of silicon microparticle internalization on cell cycle has been evaluated in
endothelial cells using flow cytometry [88]. At 12 and 24 hr following microparticle
introduction (10:1; microparticle:cell) DNA content, analyzed by propidium iodide staining,
showed no difference in relative cell cycle composition compared to control cells. In
contrast, cellular exposure to Cisplatin, a common chemotherapeutic agent, inhibited cellular
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mitosis as evidenced by a reduction in the G2/M peak. Flow cytometry analysis of the
apoptotic volume, that is, cells with cell volume loss or cell shrinkage, confirmed a major
accumulation of cell fragments following Cisplatin treatment, but no evidence of cell death
due to cellular uptake of microparticles.
Since foreign material can elicit an immune response, induction of cytokine release
following exposure of endothelial cells to silicon microparticles has been assessed by
measuring two pro-inflammatory cytokines, IL-6 and IL-8, in the cell media. While positive
control zymosan particles elicited a prominent increase in cytokine production, no
significant increase was seen after microparticle exposure for 1, 4, and 24 hr. In summary,
studies to date have shown that endothelial cells are unaffected by the presence of porous
silicon microparticles based on analysis of cell morphology, viability, cell cycle, apoptosis,
and mitosis. Similarly, macrophages display no impairment of cellular function in the
presence of silicon microparticles based on cell morphology, viability, and inflammatory
response (data pending publication).
9. Conclusions
Multi-stage delivery systems exemplify the progressive evolution of nanovectors. Based on
rational design, well established silicon technologies have been adapted for the fabrication
of nanovectors with specific shapes, sizes, and porosities. These vectors are part of a multi-
stage delivery system that contains multiple nano-components, each designed to achieve a
specific task with the common goal of site-directed delivery of therapeutics to a target
lesion. Quasi-hemispherical and discoidal silicon microparticles have been found to be
superior to spherical particles with respect to margination in the blood, and particles of
different shapes and sizes have unique distributions in vivo. Cellular adhesion and
internalization of silicon microparticles is influenced by microparticle shape and surface
charge, with the latter affecting binding by serum opsonins. The presence of inflammatory
cytokines has been shown to enhance cellular uptake of silicon microparticles by both
endothelial cells and macrophages. Based on in vitro studies, internalization of porous
silicon microparticles is compatible with cellular morphology, intracellular trafficking,
mitosis, cell cycle progression, cytokine release, and cell viability.
Abbreviations
MDS multi-stage delivery system
PEG poly (ethylene glycol)
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
HMVEC Human MicroVascular Endothelial Cell
HUVEC Human Umbilical Vein Endothelial Cell
APTES 3-aminopropyltriethoxysilane
Qdots quantum dots
RES reticulo-endothelial system
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Figure 1.
The schematic representation of three generations of nanovectors shows first generation
vectors with passive tumor targeting by means of EPR (top), followed by externally
activated (A) or actively targeted (B) second generation vectors (middle), and multi-
functional, third generation vectors comprised of multiple components that perform time-
sequences of events (bottom). Reproduced from Sakamoto et al [90] courtesy of Elsevier.
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Figure 2.
Flow chamber determination of the number of particles (n), based on shape, marginating
towards endothelial cells per second as a function of shear rate. Discoidal particles
marginate at the highest frequency for all shear rates, followed by quasi-hemispherical
particles, and then spherical particles. Reproduced from Gentile et al. [40], courtesy of
Elsevier.
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Figure 3.
Tissue distribution of silicon relative to the injected dose of silicon microparticles. The
percentage of silicon is reflective of the number of particles of various shapes accumulating
in each organ 6 hrs after intravascular injection of microparticles into mice containing
orthotopic breast tumors. Reproduced from Decuzzi et al.[43], courtesy of Elsevier.
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Figure 4.
Outline of the fabrication protocol for porous silicon particles (a–d) and SEM micrographs
of the resulting particles (e–g). (a) A silicon substrate masked with silicon nitride is
patterned through photolithography; (b) trenches are formed in the silicon by reactive ion
etch; (c) the trenches are selectively porosified by electrochemical etch in a solution of
hydrofluoric acid and ethanol; (d) the particles are released from the substrate by sonication
in isopropanol; (e) backside of a 1.6 µm particle laying on the external corona of a 3.2 µm
particle; (f) overview of a collection of 3.2 µm discoidal particles. (g) left: typical porous
structure ranging from 10 to 20 nm; right: typical porous structure for pores larger than 20
nm.
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Figure 5.
Biocompatibility of porous silicon microparticles. A) Scanning electron micrographs show
endothelial binding (left) and internalization (right) of silicon (Si) microparticles loaded with
gold nanoparticles (scale bars 1 µm). B) Endothelial proliferation (formazan absorbance at
570 nm) is unaffected by either control or nanoparticle [iron oxide (IO) or gold (Au)] loaded
silicon microparticles (left 5:1; right 10:1; particles:cells). Adapted from Serda et al. [88],
courtesy of RSC Publishing.
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Figure 6.
Loading of annamycin liposomes into porous silicon microparticles. Fluorescence associated
with hemispherical nanoporous particles before (left panel) and after (right panel) loading.
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Figure 7.
Scanning electron micrographs show endothelial binding and engulfment of 1.6 µm (top
row) and 3.2 µm (bottom row) silicon microparticles [bars 5 µm (left) and 1 µm (right)].
Reproduced from Serda et al. [88], courtesy of RSC Publishing.
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Figure 8.
Endothelial cells internalize silicon microparticles by rearrangement of the actin
cytoskeleton. Transmission electron micrographs show internalization of larger, 3.2 µm
particles by phagocytosis (A) and smaller, 1.6 µm, particles by macropinocytosis (B).
Adapted from Serda et al. [87], courtesy of Elsevier.
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Figure 9.
Endothelial cells undergo mitosis with equal partitioning of silicon microparticle-
encapsulated endosomes between the daughter cells, as captured by real-time confocal
imaging. Adapted from Serda et al. [88], courtesy of RSC Publishing.
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